PCV51 Cost-Effectiveness of Rivaroxaban for the Prevention of Stroke and Systemic Embolism in Adult Patients With Non-Valvular Atrial Fibrillation with One or More Risk Factors – A UK Perspective
Abstract
Authors
Y. Asukai A. Duran A. Lloyd E.J. McLeod T. Evers J. Broughton